BioSpace News Archive

Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.

Gracell Biotechnologies Inc. today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET.

Biofrontera Inc. (Nasdaq:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that the U.S. Patent and Trademark Office (USPTO) has granted a new patent to Biofrontera Bioscience GmbH related to a photodynamic therapy (PDT) protocol that is expected to be less painful but similarly effective to conventional PDT.

SOPHiA GENETICS, a cloud-native software company and the leader in data-driven medicine, celebrates with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 samples analyzed for HRD status.

Moss Genomics Inc. (CSE: MOSS) (“Moss” or the “Company”), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, announces signing of a memorandum of understanding (“MOU”) with Proteic Bioscience Inc. (“Proteic”).

The Insight Partners published latest research report on “Global Artificial Intelligence in Healthcare Diagnosis Market Size Report, Share, Trends, Growth & Forecast to 2027 – COVID-19 Impact and Global Analysis – By Diagnostic Tool; Application; End User; and Service”, the global market is expected to reach USD 66,811.97 million by 2027 from USD 3,639.02 million in 2019.

The Insight Partners published latest research report on “Medical Affairs Outsourcing Market Overview Report, Size, Share, Trends & Growth Forecast to 2027 - COVID-19 Impact and Global Analysis By Services and Application, and Geography”, the global market share is projected to reach USD 3,287.12 million by 2027 from USD 1,415.00 million in 2019; it is estimated to grow at a CAGR of 11.2% from 2020 to 2027.

ChomiX Biotech Co., Ltd. announced the completion of millions of dollars Pre-A+ Financing by TigerYeah Capital,old shareholder Tsinghua Innovation Ventures, and Morning Spring Venture.

BiOneCure Therapeutics, Inc. has announced a strategic collaboration with Nanjing Leads Biolabs to develop a range of innovative anti-drug conjugates (ADCs) for treating solid tumors.

Mozart Therapeutics today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting demonstrating the potential of its lead therapeutic, a targeted, bispecific CD8 Treg modulator, as a new therapeutic treatment approach for autoimmune diseases.